Antitumoral melatonin-loaded nanostructured lipid carriers

Area of Science:

• Nanotechnology in Medicine
• Cancer Therapeutics
• Pharmacology

Background:

• Cancer is a leading global cause of death with limited conventional therapy options.
• Melatonin (MEL), a natural compound, shows antitumoral properties but is limited by instability and poor solubility.
• Developing stable and effective drug delivery systems for natural compounds is crucial for cancer treatment.

Purpose of the Study:

• To enhance the stability and antitumoral activity of melatonin (MEL) by encapsulating it into nanostructured lipid carriers (MEL-NLC).
• To investigate the physicochemical properties, stability, and in vitro antitumoral efficacy of MEL-NLC.
• To evaluate MEL-NLC as a potential alternative cancer therapy.

Main Methods:

• Optimization of MEL-NLC using a design of experiments approach.
• Characterization of MEL-NLC for physicochemical properties, stability, and drug release kinetics.
• In vitro assessment of MEL-NLC cytotoxicity against various cancer cell lines and healthy cells.

Main Results:

• Optimized MEL-NLC showed favorable physicochemical characteristics, including small particle size and sustained melatonin release.
• MEL-NLC exhibited long-term stability, addressing a key limitation of free melatonin.
• In vitro studies confirmed selective cytotoxicity of MEL-NLC against cancer cells, with minimal impact on healthy cells.

Conclusions:

• MEL-NLC formulation enhances melatonin's stability and delivery for cancer treatment.
• The nanostructured lipid carrier system demonstrates targeted and selective antitumoral activity.
• MEL-NLC presents a promising, potentially less toxic, alternative to conventional cancer therapies.